Search research articles
Contact Us
Filters
Showing results (31-40 of 72) with videos related to
Page
of 8
Sort By:
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Transplantation and Cellular Therapy
|
March 30, 2021
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Doris K Hansen, Jongphil Kim, Zachary Thompson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 20, 2025
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma
Ciara L Freeman, Julieta Abraham-Miranda, Meghan Menges, et al.
Transplantation and Cellular Therapy
|
December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Othman S Akhtar, Karnav Modi, Jongphil Kim, et al.
Cancers
|
October 14, 2023
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
Laura B Oswald, Lisa M Gudenkauf, Xiaoyin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
European Journal of Haematology
|
May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma
Grace Elsey, James A Davis, Kelley Julian, et al.
Transplantation and Cellular Therapy
|
September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium
Karen Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica
|
October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
Hamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Open Forum Infectious Diseases
|
October 16, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation
Guy Handley, Amanda Yepes, Eva Eliassen, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 72) with videos related to
Sort By:
Page
of 8
Journal of Hematology & Oncology
|
July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Transplantation and Cellular Therapy
|
March 30, 2021
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Doris K Hansen, Jongphil Kim, Zachary Thompson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 20, 2025
Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma
Ciara L Freeman, Julieta Abraham-Miranda, Meghan Menges, et al.
Transplantation and Cellular Therapy
|
December 20, 2023
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Othman S Akhtar, Karnav Modi, Jongphil Kim, et al.
Cancers
|
October 14, 2023
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
Laura B Oswald, Lisa M Gudenkauf, Xiaoyin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2023
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Doris K Hansen, Surbhi Sidana, Lauren C Peres, et al.
European Journal of Haematology
|
May 18, 2026
Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma
Grace Elsey, James A Davis, Kelley Julian, et al.
Transplantation and Cellular Therapy
|
September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium
Karen Sweiss, Charlotte Wagner, Eric Anto, et al.
Haematologica
|
October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
Hamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Open Forum Infectious Diseases
|
October 16, 2024
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation
Guy Handley, Amanda Yepes, Eva Eliassen, et al.
Page
of 8